Point72 Asset Management’s Fusion Pharmaceuticals FUSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-293,611
Closed -$2.82M – 2727
2023
Q4
$2.82M Sell
293,611
-35,257
-11% -$171K 0.01% 1096
2023
Q3
$855K Hold
328,868
– – ﹤0.01% 1373
2023
Q2
$1.54M Hold
328,868
– – ﹤0.01% 1081
2023
Q1
$1.24M Hold
328,868
– – ﹤0.01% 1070
2022
Q4
$1.04M Buy
328,868
+18,800
+6% +$46.8K ﹤0.01% 1040
2022
Q3
$933K Sell
310,068
-18,800
-6% -$46.9K ﹤0.01% 1077
2022
Q2
$819K Sell
328,868
-21,132
-6% -$97.1K ﹤0.01% 1114
2022
Q1
$2.72M Sell
350,000
-698,956
-67% -$5.07M 0.01% 824
2021
Q4
$4.37M Buy
1,048,956
+190,944
+22% +$1.19M 0.02% 701
2021
Q3
$6.8M Sell
858,012
-17,129
-2% -$144K 0.03% 593
2021
Q2
$7.07M Buy
875,141
+125,141
+17% +$1.08M 0.03% 529
2021
Q1
$8.04M Buy
750,000
+200,000
+36% +$2.34M 0.04% 475
2020
Q4
$6.46M Buy
+550,000
New +$6.91M 0.03% 538
2020
Q3
– Sell
-60,000
Closed -$1.05M – 1136
2020
Q2
$1.05M Buy
+60,000
New +$1.05M 0.01% 669

Other funds holding FUSN

Point72 Asset Management's FUSN Position: Q1 2024 in Review

Point72 Asset Management sold out of Fusion Pharmaceuticals (FUSN) in Q1 2024, closing a stake of 293,611 shares — an estimated $2.82M sold.

Point72 Asset Management first reported a position in FUSN in Q2 2020 and held it in 14 quarters. The position peaked at $8.04M in Q1 2021. 114 funds tracked by Wall St. Rank hold FUSN as of Q1 2024.

  • Point72 Asset Management reported no remaining Fusion Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Point72 Asset Management sold 293,611 Fusion Pharmaceuticals shares in Q1 2024, an estimated $2.82M.
  • Point72 Asset Management first reported a position in Fusion Pharmaceuticals in Q2 2020 and held it in 14 quarters.
  • Point72 Asset Management's Fusion Pharmaceuticals position peaked at $8.04M in Q1 2021.
  • 114 funds tracked by Wall St. Rank held Fusion Pharmaceuticals as of Q1 2024.

Based on Point72 Asset Management's 13F filing for Q1 2024, filed 15 May 2024.